Cernostics’ Series B funding will further develop a breakthrough diagnostic platform, producing comprehensive risk prediction for the development of esophageal cancer in patients with Barrett’s Esophagus. Read more.
Client & Alumni News
Cernostics’ Series B funding will further develop a breakthrough diagnostic platform, producing comprehensive risk prediction for the development of esophageal cancer in patients with Barrett’s Esophagus. Read more.